📊 NXL Key Takeaways
Is Nexalin Technology, Inc. (NXL) a Good Investment?
Nexalin exhibits exceptional revenue growth (+3,761% YoY) with healthy gross margins (79.7%), indicating viable product unit economics. However, the company faces critical financial distress: operating losses of $8.4M against only $301.6K in revenue, combined with negative free cash flow of -$5.0M annually and just $654.8K in cash, implies approximately 1.6 months of runway. Immediate dilutive capital raise or dramatic cost restructuring is essential for survival.
Why Buy Nexalin Technology, Inc. Stock? NXL Key Strengths
- Exceptional gross margin of 79.7% demonstrates strong product-market economics and pricing power
- No long-term debt (0.00x debt-to-equity) eliminates financial leverage risk
- Strong short-term liquidity ratios (4.85x current ratio) provide near-term flexibility
NXL Stock Risks: Nexalin Technology, Inc. Investment Risks
- Critical cash burn: -$5.0M annual operating cash flow against only $654.8K cash ($1.6M runway at current burn)
- Unsustainable unit economics at scale: -2,726% net margin indicates opex/R&D massively exceed revenue; business model unproven at larger scale
- Imminent capital raise necessity creates severe shareholder dilution risk; company likely requires external funding within weeks to survive
Key Metrics to Watch
- Cash burn rate and actual cash balance - critical for survival timeline
- Revenue trajectory post-commercialization - must accelerate significantly to justify expense base
- Operating expense levels and SG&A efficiency - path to profitability depends on dramatic cost reduction or 10x+ revenue growth
Nexalin Technology, Inc. (NXL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.85x current ratio provides a solid financial cushion.
NXL Profit Margin, ROE & Profitability Analysis
NXL vs Healthcare Sector: How Nexalin Technology, Inc. Compares
How Nexalin Technology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nexalin Technology, Inc. Stock Overvalued? NXL Valuation Analysis 2026
Based on fundamental analysis, Nexalin Technology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nexalin Technology, Inc. Balance Sheet: NXL Debt, Cash & Liquidity
NXL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nexalin Technology, Inc.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-0.83 indicates the company is currently unprofitable.
NXL Revenue Growth, EPS Growth & YoY Performance
NXL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.1K | -$2.3M | $-0.13 |
| Q2 2025 | $26.8K | -$1.3M | $-0.10 |
| Q1 2025 | $41.0K | -$1.0M | $-0.14 |
| Q3 2024 | $24.1K | -$2.3M | $-0.23 |
| Q2 2024 | $26.8K | -$822.4K | $-0.11 |
| Q1 2024 | $30.6K | -$748.4K | $-0.10 |
| Q3 2023 | $24.1K | -$135.4K | $-0.03 |
| Q2 2023 | $35.5K | -$393.2K | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nexalin Technology, Inc. Dividends, Buybacks & Capital Allocation
NXL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nexalin Technology, Inc. (CIK: 0001527352)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NXL
What is the AI rating for NXL?
Nexalin Technology, Inc. (NXL) has an AI rating of STRONG SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NXL's key strengths?
Claude: Exceptional gross margin of 79.7% demonstrates strong product-market economics and pricing power. No long-term debt (0.00x debt-to-equity) eliminates financial leverage risk.
What are the risks of investing in NXL?
Claude: Critical cash burn: -$5.0M annual operating cash flow against only $654.8K cash ($1.6M runway at current burn). Unsustainable unit economics at scale: -2,726% net margin indicates opex/R&D massively exceed revenue; business model unproven at larger scale.
What is NXL's revenue and growth?
Nexalin Technology, Inc. reported revenue of $301.6K.
Does NXL pay dividends?
Nexalin Technology, Inc. does not currently pay dividends.
Where can I find NXL SEC filings?
Official SEC filings for Nexalin Technology, Inc. (CIK: 0001527352) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NXL's EPS?
Nexalin Technology, Inc. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NXL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nexalin Technology, Inc. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NXL stock overvalued or undervalued?
Valuation metrics for NXL: ROE of -219.4% (sector avg: 15%), net margin of -2,725.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NXL stock in 2026?
Our dual AI analysis gives Nexalin Technology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NXL's free cash flow?
Nexalin Technology, Inc.'s operating cash flow is $-5.0M, with capital expenditures of N/A. FCF margin is -1,643.5%.
How does NXL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,725.8% (avg: 12%), ROE -219.4% (avg: 15%), current ratio 4.85 (avg: 2).